Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media.

Academic Article


  • BACKGROUND: We report the incidence of contrast-induced acute kidney injury (CI-AKI) following administration of iodixanol or low-osmolar contrast media (LOCM) in patients for suspected peripheral arterial occlusive disease (PAOD) undergoing intra-arterial digital angiography (IA-DSA). METHODS: IA-DSA was performed according to site standard for contrast agent type and volume following computed tomography (CT) of the abdominal aortoiliac and lower extremity arteries and a washout period of at least 3 days. Serum creatinine was measured at baseline and 24 ┬▒ 4 hours after contrast administration. CI-AKI was defined as laboratory increase of serum creatinine value =25% from baseline measurement at 24 hours. The incidence of CI-AKI was analyzed with chi-square statistics. RESULTS: Of the 250 patients who underwent IA-DSA with complete data for analysis, 147 (58.8%) received iodixanol and 103 (41.2%) received LOCM (iopamidol, 91; ioversol, 7; iohexol, 3; iopromide, 2). Baseline mean serum creatinine was statistically higher for iodixanol compared with LOCM (100 vs. 82.7 ┬Ámol/L; p=0.0124). CI-AKI occurred in 8 patients (5.4%) with iodixanol and 14 patients (13.6%) with LOCM (p=0.025). Further analysis showed that iopamidol administration was responsible for the 13 out of 14 cases of CI-AKI in LOCM patients. CONCLUSIONS: In patients with suspected PAOD undergoing IA-DSA, the incidence of CI-AKI at 24 hours following contrast administration was significantly less for patients who received iodixanol compared with various LOCM; this difference was primarily driven by iopamidol.
  • Published In


  • Acute Kidney Injury, Adult, Aged, Aged, 80 and over, Angiography, Digital Subtraction, Contrast Media, Creatinine, Female, Humans, Iopamidol, Male, Middle Aged, Triiodobenzoic Acids
  • Pubmed Id

  • 16621365
  • Author List

  • Karlsberg RP; Dohad SY; Sheng R; Iodixanol Peripheral CTA Study Investigator Panel
  • Start Page

  • 658
  • End Page

  • 666
  • Volume

  • 23
  • Issue

  • 6